Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities

Core Insights - Amarin Corporation has achieved significant operational milestones in 2025, including a positive cash flow in Q4 2025, ahead of expectations, and is on track for sustainable positive annual cash flow in 2026 [2][3]. Financial Highlights - The year-end 2025 cash balance was $303 million, an increase of $16 million from $287 million in Q3 2025 [6]. - Q4 2025 net revenue is expected to range between $48 - $53 million, while FY 2025 net revenue is projected to be between $212 - $217 million [6]. - The company realized approximately 50% of the estimated $70 million in OPEX savings from its restructuring plan, with full savings expected by June 30, 2026 [6]. Operational Accomplishments - VASCEPA maintained market leadership with over 50% share of IPE prescriptions by year-end 2025 [6]. - Amarin entered into a long-term partnership with Recordati S.p.A. to commercialize VAZKEPA in 59 countries, focusing on Europe [3][6]. - The company secured pricing and reimbursement in Austria and Slovenia, enhancing market access [6]. Strategic Outlook - In 2026, Amarin aims to maintain its IPE leadership in the U.S. and expand its therapeutic reach across Europe and other international markets [9]. - The company is actively pursuing additional strategic opportunities to unlock shareholder value [3][9]. - Amarin's commercialization strategy is now asset-light, leveraging partnerships to enhance efficiency and market reach [9].